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Summary. In this study we determined the potential bone 
marrow toxicity of the ether lipid derivatives 1-0-octa- 
decyl-2-0-methyl-rac-glycero-3-phosphocholine (OcMe-G- 
3-PC), 1-0-hexadecyl-propanediol-2-phosphocholine (He- 
Pr-2-PC), and hexadecylphosphocholine (H -PC). OcMe- 
G-3-PC inhibited the proliferation of mouse granulocyte- 
macrophage progenitor cells (GM-CFCs) at a dose of 
1 p.g/ml, whereas He-Pr-2-PC and He-PC started to inhibit 
the growth of hemopoietic precursors at 5 ~g/ml. In con- 
trast to this finding, NMRI mice given l0 mg/kg i.v. daily 
for 4 weeks and 20 or 30 mg/kg for 5 days showed no bone 
marrow toxicity. We conclude that the dose-dependent 
toxic effects observed in vitro are within the physiological 
tolerance in vivo. 
Introduction 
Both naturally occurring and synthetically prepared ether 
lipids show a variety of biological properties uch as ac- 
tivation of macrophages [16, 17], platelet aggregation and 
serotonin release [1, 2, 20], inhibition of neoplastic ell in- 
vasion in normal tissue [21], influence on diffusion charac- 
teristics of biological membranes [22, 23], induction of dif- 
ferentiation of malignant cells [13, 14], and cytotoxicity 
against umor cells in vitro and in vivo [3, 5, 9, 17, 18]. One 
of the intriguing and promising aspects of tumor chemo- 
therapy with ether lipids is that, unlike essentially all other 
antitumor agents, these compounds are incorporated into 
and interact with the cell membrane, not with the nucleus. 
In addition, some selected ether lipids have been shown to 
display selective antineoplastic activity against leukemic 
cells compared with normal bone marrow progenitor cells 
in vitro [19, 25] and against the methylnitrosourea 
(MNU)-induced rat mammary carcinoma in vivo [5, 10, 
11, 18]. In view of increasing evidence of the antineoplas- 
tic effect of some ether lipids, we deemed it important to 
investigate possible hematotoxic side effects. Three selected 
ether lipids were investigated for possible toxic effects 
on bone marrow cells in vitro and in vivo. 
Materials and methods 
1-0-Octadecyl-2-0-methyl-rac-glycero-3-phosphocholine 
(OcMe-G-3-PC), l-0-hexadecyl-propanediol-2-phospho- 
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choline (He-Pr-2-PC), and hexadecylphosphocholine 
(He-PC) were synthesized in our laboratory as previously 
described by Eibl [7, 8]. 
Isolation of murine bone marrow cells. Femurs of mice were 
removed and denuded under aseptic conditions. Bone 
marrow cells were flushed out with a 24-gauge needle. The 
cells were suspended in RPMI-1640 medium (Biochrom, 
Berlin, FRG) and counted in a Neubauer chamber prior to 
culturing. 
Preparation of WEHI-3B conditioned medium. The murine 
myelomonocytic cell line WEHI-3B was grown in RPMI- 
1640 medium supplemented with 20 mM HEPES, 4 mM 
L-glutamine, 200 p~g/ml streptomycin/penicillin (Bio- 
chrom, Berlin, FRG), and 10% fetal calf serum (Gibco, 
Karlsruhe, FRG) until the cells were in a logarithmic 
growth phase. The culture medium was then changed and 
the cells were incubated for 2 to 3 additional days. There- 
after, the cell medium was removed, centrifuged, and dia- 
lyzed against distilled water for 3 days, with daily changes 
of the dialyzing fluid. 
Agar cultures. The agar cultures were prepared according 
to the method of Metcalf [15]. In short, 1 ml agar culture 
medium consisting of equal volumes of double-strength 
Dulbecco's Modified Eagle's Medium (DMEM; Gibco, 
Karlsruhe, FRG) and 0.6% Bacto-Agar (Difco; Detroit, 
Michigan, USA) in distilled water, 50,000 bone marrow 
cells, 10% WEHI-3B conditioned medium as a growth fac- 
tor source, and either ether lipid solution or phosphate- 
buffered solution (PBS) as a control was plated in 35-mm 
petri dishes. The plates were incubated at 37°C under a 
fully humidified atmosphere and 6.5% CO2. Colonies were 
scored after 7 days; only those containing >40 cells were 
taken into account. 
Animal experiments. Female NMRI mice (8-12 weeks old, 
25-30 g) were used in the study. Ether lipids were dis- 
solved at varying concentrations in 0.9% NaC1 containing 
0.5% (w/v) bovine serum albumin. Aliquots of 200 p.l ether 
lipid solution or 0.9% NaC1 were injected via the tail vein. 
The mice were divided in three groups: one group received 
a dose of 10 mg/kg daily for 4 weeks (5 days/week), and 
the second and third groups were treated with daily injec- 
tions of 20 and 30 mg/kg, respectively, for 5 days. The 
mice were killed 5 days after the termination of treatment 
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Fig. 1. Chemical structures of the various ether lipids. A, 1-0- 
Octadecyl-2-0-methyl-rac-glycero-3-phosphocholine (OcMe-G- 
3-PC); B, 1-0-hexadecyl-propanediol-2-phosphocholine (He-Pr- 
2-PC); C, hexadecylphosphocholine (He-PC) 
and the bone marrow was withdrawn for stem-cell culture 
experiments. 
Results and discussion 
The organ most frequently affected by cancer chemother- 
apeutic agents is the bone marrow. Because of differences 
in the peripheral blood half-life of erythrocytes, leuko- 
cytes, and platelets, the latter two are obviously most fre- 
quently involved in early suppression by chemotherapy 
[12]. Therefore, the inhibition of in vitro colony formation 
of granulocyte-macrophage progenitor cells (GM-CFCs) 
may represent a relevant, sensitive reference to toxic ef- 
fects of ant±neoplastic agents. 
The chemical structures of the ether l ipid derivatives 
used in this study are given in Fig. 1. There are three rea- 
sons why these compounds were selected for the investiga- 
tion of possible hematotoxic side effects. First, they repre- 
sent main classes in a broad spectrum of structural varia- 
tions of cytotoxic ether l ipids; second, they can inhibit 
tumor growth in vitro and in vivo [3, 5, 9, 17, 24]; and 
third, two of the selected ether lipids have recently been 
introduced into clinical phase I trials [4, 24]. 
Table 1 summarizes the in vitro effects of these deriva- 
tives on granulocyte-macrophage colony formation in nor- 
mal murine bone marrow progenitor cells. The compounds 
display a concentration-dependent inhibition of colony 
formation of GM-CFCs.  The inhibitory effect of OcMe-G- 
3-PC was observed even at a concentration ofabout 1 ktg/ml, 
whereas He-PC and He-Pr-2-PC revealed inhibition at 
a concentration of about 5 lxg/ml. Thus, in comparison 
with OcMe-G-3-PC, the latter two compounds are about 
Table 1. In vitro effect of ether lipids on clonogenicity of normal 
bone marrow granulocyte-macrophage progenitors 
Compound Number of colonies a (% of control) 
Concentrations of ether lipids (ktg/ml) 
0.1 1.0 5.0 10.0 20.0 
OcMe-G-3-PC 92±8.8 66±5.5 15+7.7 5± 3.6 2± 0.7 
He-PC 90±0.7 91±4.4 63±5.3 25±11.4 17±11.5 
He-Pr-2-PC 98±4.0 98±2.1 61±6.1 30± 8.1 19± 3.5 
a Means ± SD of 3 -  5 independent experiments 
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5 times less toxic. This may partial ly be explained by a dif- 
ference in the length of the alkyl chain; it is known that 
alkyl lysophospholipids with a C 18 chain are more toxic to 
leukemic cells in vitro than those with a C16 chain [17]. 
In the in vivo experiments, the mice were given daily 
i.v. doses of 10 mg/kg ether lipids for 4 weeks or 20 or 
30 mg/kg for 5 days, respectively. In contrast to the results 
obtained in vitro, no inhibition of colony formation could 
be observed (Table 2). In fact, even a moderate increase in 
the blood leukocyte count was noticed after the end of 
therapy in the mice treated with 20 or 30 mg/kg (Table 3). 
As the leukocytes appeared to be mature in blood-smear 
specimens, an activation of the marginal leukocyte pool 
might have been responsible for this observation. 
It is noteworthy that a daily oral dose of 4mg/kg  
He-PC given for 4 weeks is sufficient o reduce significantly 
the growth rate of dimethylbenzanthracene (DMBA)-in- 
duced mammary carcinomas in the rat [11]. Doses of 
10 mg/kg and more can effect a regression of the tumor 
throughout the period of treatment [11], independent of its 
size at the start of treatment. 
The difference between toxic levels in vitro and in vivo 
are not fully understood. One reason could be that ether 
l ipids are metabolized in vivo and cleared rapidly. Howev- 
er, it has been shown that He-PC catabolism in mice oc- 
curs very slowly [6]. The most plausible explanation may 
be the lack of the natural environment of bone marrow 
progenitors under in vitro conditions, which makes these 
immature cells more susceptible to any challenge. In con- 
Table 2. In vivo effect of ether lipids on clonogenicity of normal 
bone marrow granulocyte-macrophage progenitors 
Compound Number of colonies a (% of control) 
Ether lipid dose (mg/kg) 
10 20 30 
OcMe-G-3-PC 87 ± 6.4 93 ± 1.5 79± 6.6 
93+ 3.6 73± 9.1 158±11.5 
88±13.7 106± 6.6 135+ 2.1 
He-PC 101 ± 3.0 84± 14.5 101 ± 7.3 
118___10.5 89± 3.4 148± 7.3 
73± 1.5 84+ 6.5 70±15.1 
He-Pr-2-PC 125± 10.9 107+ 10.8 142± 8.7 
98± 8.4 152±18.1 157+ 8.2 
76± 7.8 117+ 4.9 141±10.4 
a Data represent the means ± SD of triplicate cultures. Mice were 
treated i.v. with 10 mg/kg ether lipids for 4 weeks and with 20 or 
30 mg/kg for 5 days 





Total white cell count ( x 109/1) 
OcMe-G-3-PC He-PC He-Pr-2-PC 
l0 2.4±0.6 2.7±0.6 3.0±0.3 
20 6.4±0.3 6.2±0.9 5.9±1.7 
30 4.6±1.0 4.4±1.5 6.1±0.9 
Data represent the means ± SD of triplicate determinations. 
Controls: 3.2 _+ 1.6 
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clusion, the absence of in vivo hematotoxicity and simul- 
taneous activity against umor cells should offer a great 
advantage for the use of cytotoxic ether lipids in cancer 
therapy. 
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